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A 42-year-old man presented at our attention with chest pain. His cardiac risk factors were smoking habit and family history of
coronary artery disease. At the ECG, a mild ST-segment elevation in the inferior leads was shown. A normal left ventricular func-
tionwasdemonstratedattheechocardiography.Anemergencycoronaryangiographywasperformed,andanextensivethrombosis
of the right coronary artery and midleft anterior descending coronary artery was visualized. A primary angioplasty with thrombus
aspiration and direct stenting of both sites followed. Biochemical analysis revealed a high plasma homocysteine level with a homo-
zygotic anomaly of the 5,10-methylenetetrahydrofolate reductase. Currently, a nine-month followup negative for cardiac events is
recorded.
1.Introduction
Simultaneous thrombosis of multiple epicardial coronary
arteries is an uncommon angiographic ﬁnding in ST-seg-
ment elevation myocardial infarction. It is related to several
factors such as diﬀuse vessel spasm, state of hypercoagulabil-
i t y ,a n dad e c r e a s e dc o r o n a r yb l o o dp r e s s u r e[ 1].
Hyperhomocysteinemiaisariskfactorofcoronaryartery
disease associated to arterial thrombosis. It is characterized
byanabnormallyhighconcentrationofhomocysteine(asul-
furated amino acid produced through the methionine me-
tabolism).
ThispaperdescribesacaseofST-segmentelevationmyo-
cardial infarction secondary to thrombosis of two coronary
arteries in a patient aﬀected by intermediate hyperhomocys-
teinemia gene mutation related.
2. Case Presentation
A 42-year-old male presented at the emergency room of
the Hospital Policlinico, Milan, Italy with chest pain. He
did not have any medical disease including hypertension,
diabetes mellitus, dyslipidemia, and denied cocaine abuse.
He was a smoker with familial premature coronary artery
disease history; his body mass index was 22.6. The vital signs
were normal (blood pressure: 130/80mmHg, heart rate:
73bpm, and oxygen saturation: 100%), and physical exam-
ination revealed no abnormalities. A 2mm ST-segment ele-
vationintheinferiorleadswasdocumentedattheelectrocar-
diogram. After an initial medical treatment with unfraction-
atedheparin,acetylsalicylicacid,andclopidogrel,thepatient
was transported to the catheterization laboratory. The coro-
nary angiogram revealed a normal left main and circumﬂex
artery and two luminal irregularities of right coronary artery
(RCA) and left anterior descending artery (LAD) compli-
cated by wide coronary thrombosis (Figures 1(a) and 1(c)).
Then, a glycoprotein IIb/IIIa inhibitor was administered
according to standard protocol and thrombus aspiration,
followed by direct stent implantation in the mid-RCA and
mid-LAD (resp., with two and one bare metal stent), which
weresuccessfullyperformed(Figures1(b)and1(d)).Atrans-
thoracic echocardiogram showed a mildly reduced left ven-
tricular function (ejection fraction 53%) with a normal right
ventricular size and function.
A moderately high plasma homocysteine level
(>50µmol/L) with normal serum vitamin B12 and folate
levels were found at the biochemical analysis, together with
normal renal and serum lipid proﬁles. A mild increase of2 Cardiology Research and Practice
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troponin T (peak 0.31ng/mL, normal range: 0.00–0.03) was
detected. The thrombophilia screening ﬁndings are shown
in Table 1. The genetic testing for the methylenetetrahydro-
folate reductase showed the presence of C677T mutation
in homozygosis. Therefore, oral folic acid supplementation
(5mg/die) was initiated. Currently, a nine-month followup
negative for cardiac events is recorded; the plasma homo-
cysteine level remained at the upper normal limit after me-
thionine treatment.
3. Discussion and Conclusion
Simultaneous multivessel thrombosis in the setting of acute
myocardial infarction is a rare entity. A case of acute throm-
bosis of two simultaneous coronary arteries in a young adult
with familial hyperhomocysteinemia is described.
Numerous studies have indicated that an increased plas-
ma homocysteine level is a risk factor for occlusive arterial or
venous disease [2–4].
Hyperhomocysteinemia usually occurs in people with at
least one defective gene that aﬀects the breakdown of ho-
mocysteine. There are two common defective genes in the
population. The ﬁrst one is related to the enzyme methylene-
Table 1: Summary of thrombophilia screening laboratory ﬁndings.
Tests Results (normal range)
Prothrombin time 10.80 seconds (8.9–11.7)
International normalized ratio (INR) 0.96 (0.90–1.14)
Activated partial thromboplastin time 25.7 (24.5–35.2)
Homocysteine (Hcy) >50µmol/L (4.00–15.40)
Protein C activity (%) 122% (72–160)
Protein S activity (%) 152% (79–183)
Antithrombin III activity 108.0% (82.0–112.0)
Factor V Leiden mutation Negative
Prothrombin gene mutation Negative
Phospholipid (cardiolipin) AB IgG 1.8U/mL GPL (0–10)
Phospholipid (cardiolipin) AB IgM 0.0U/mL MPL (0–10)
Lupus anticoagulant Absent
tetrahydrofolatereductase, the second to the methioninesyn-
thetase. Other causes of hyperhomocysteinemia are repre-
sented by deﬁciency of vitamin B, impaired renal function,
and negative lifestyle factors (smoking habit, coﬀee abuse,
and sedentary lifestyle). [5, 6] Hyperhomocysteinemia isCardiology Research and Practice 3
classiﬁed as mild-moderate (15–30µmol per liter), interme-
diate (>31–100µmol per liter), and severe (>100µmol per
liter) [7].
Subjects with moderate hyperhomocysteinaemia are
characterized by a prothrombotic, and dysﬁbrinolytic state
and homocysteine level is an independent predictor of
thrombotic events. [8] The oxidative injury of endothelium
in homocysteinaemia, combined with the lack of vasculo-
protective eﬀects of nitric oxide, predisposes to thrombotic
events [8]. It is now widely accepted that increased plasma
homocysteine is associated with increased cardiovascular
risk independently of other atherosclerosis risk factors. [9]
However, it is still unclear whether plasma homocysteine can
be approached as a modiﬁable risk factor for atherosclerosis
[10]. Our patient showed elevated homocysteine levels asso-
ciated with homozygosity for the C677T gene mutation of
methylenetetrahydrofolate reductase. A signiﬁcantly higher
frequency of this genetic condition was found in patients
with early coronary artery disease onset (age <45 years) [11].
Politi et al. presented a case of a 35-year-old patient, with
extensive anterior AMI and multiple thrombotic occlusion
(in the distal LAD, diagonal branches, and obtuse marginal
branch). Also this case was associated to elevated homocys-
teine levels (>50µmol/L) with normal thrombophilic and
lipide proﬁle [12].
No routine screening for elevated homocysteine and
treatment is currently recommended except in patients who
have premature atherosclerosis [13].
Further investigation on hyperhomocysteinaemia and
coronary heart disease is needed.
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